| Literature DB >> 33728294 |
Xia Li1, Wei-Yi Xia2, Fang Jiang3, Dan-Yong Liu4, Shao-Qing Lei5, Zheng-Yuan Xia3, Qing-Ping Wu6.
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, which has lasted for nearly a year, has made people deeply aware of the strong transmissibility and pathogenicity of SARS-CoV-2 since its outbreak in December 2019. By December 2020, SARS-CoV-2 had infected over 65 million people globally, resulting in more than 1 million deaths. At present, the exact animal origin of SARS-CoV-2 remains unclear and antiviral vaccines are now undergoing clinical trials. Although the social order of human life is gradually returning to normal, new confirmed cases continue to appear worldwide, and the majority of cases are sporadic due to environmental factors and lax self-protective consciousness. This article provides the latest understanding of the epidemiology and risk factors of nosocomial and community transmission of SARS-CoV-2, as well as strategies to diminish the risk of transmission. We believe that our review will help the public correctly understand and cope with SARS-CoV-2. ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.Entities:
Keywords: COVID-19; Infection; Nosocomial; Risk; SARS-CoV-2; Transmission
Year: 2021 PMID: 33728294 PMCID: PMC7942044 DOI: 10.12998/wjcc.v9.i7.1499
Source DB: PubMed Journal: World J Clin Cases ISSN: 2307-8960 Impact factor: 1.337
Public health emergency of international concern announced by the World Health Organization
|
|
| H1N1 influenza pandemic in 2009 |
| Polio eradication in 2014 |
| Ebola virus outbreak in West Africa in 2014 |
| Zika virus outbreaks in 2016 |
| Ebola outbreak in the Democratic Republic of Congo in 2018 |
| SARS-CoV-2 outbreak in 2020 |
H1N1: Influenza A; PHEIC: Public health emergency of international concern; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; WHO: World Health Organization.
Survival of severe acute respiratory syndrome coronavirus, Middle East respiratory syndrome coronavirus, and severe acute respiratory syndrome coronavirus 2 on various materials
|
|
|
|
|
|
|
|
| Year | 2020 | 2013 | 2011 | 2005 | 2005 | 2003 |
| Location | United States | United States | Hong Kong, China | Germany | Hong Kong, China | China |
| Virus | SARS-CoV-2, SARS-CoV | MERS-CoV | SARS-CoV | SARS-CoV | SARS-CoV | SARS-CoV |
| Load applied (TCID50) | SARS-CoV-2: 105.25 in aerosols, SARS-CoV: 106.75-7.00 in aerosols | 106 in aerosols, 105 on steel and plastic | 105 on plastic | NA | Dilution solution (102-104) | 106 |
| Substrate (s) | Aerosols, plastic, stainless steel, copper, cardboard | Aerosols, steel, plastic | Plastic | Polystyrene petri dish | Paper, disposable gowns, cotton gowns | Wood board, glass, mosaic, metal, cloth, paper, filter paper, plastic |
| Temperature/RH | 21-23 °C/40% | Variable | Variable | Room temperature (21-25 °C) | Room temperature | Room temperature |
| Viability | Viable SARS-CoV-2 detected after 3 h in aerosols, no viable SARS-CoV-2 detected after 4 h on copper and 24 h on cardboard, stable after 72 h on plastic and stainless steel; no viable SARS-CoV detected after 8 h on copper and 8 h on cardboard | The viability of MERS-CoV decreased 7% at 40% RH and 89% at 70% RH in aerosols; Viable MERS-CoV tested after 48 h at 20 °C/40% RH, 8 h at 30 °C/80% RH and 24 h at 30 °C/30% RH | SARS-CoV survived for 5 d at 22-25 °C relative humidity of 40%-50% with only 1 log10 loss of titer and was viable for more than 20 d; SARS-CoV was more stable at relatively low temperatures (28 °C | SARS-CoV survived for more than 6 d and retained its infectivity for up to 9 d | SARS-CoV survived no more than 5 min to 24 h on paper, 1 h to 2 d on disposable clothing, and 5 min to 24 h on cotton clothing | SARS-CoV survived for > 72 h on the surfaces of eight materials, and > 120 h on metal, cloth and filter paper |
| Reduction in infectious titer (TCID50) | SARS-CoV-2: from 103.5 to 102.7 in aerosols, from 103.7 to 100.6 after 72 h on plastic, from 103.7 to 100.6 after 48 h on stainless steel; SARS-CoV: from 104.3 to 103.5 in aerosols, from 103.4 to 100.7 after 72 h on plastic, from 103.6 to 100.6 after 48 h on stainless steel | NA | The reduction in infectious titer was similar in solution compared with virus dried on surfaces | NA | NA | NA |
| Half-life | SARS-CoV-2 :1.1 h in aerosols, 6.8 h on plastic, 5.6 h on stainless steel, 0.8 h on copper, 3.5 h on cardboard; SARS-CoV :1.2 h in aerosols, 7.6 h on plastic, 4.2 h on stainless steel, 1.5 h on copper, 0.6 h on cardboard | The half-life of MERS-CoV ranged from 0.6 to 1 h on steel and from 0.4 to 1 h on plastic | NA | NA | NA | NA |
MERS-CoV: Middle East respiratory syndrome coronavirus; RH: Relative humidity; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2.
Measures to prevent the transmission of severe acute respiratory syndrome coronavirus 2
|
|
| Strengthen the environmental hygiene of the medical sector and the personal hygiene of medical staff |
| Standardize the management procedures for confirmed and suspected cases to reduce nosocomial transmission |
| Equip health-care workers with PPE to protect their safety |
| Strictly assess hospitalization criteria and limit nonessential visits |
| Increase public awareness and education on infectious diseases and measures to prevent the spread of diseases on an individual basis |
| Enhance supervision and management of the flow of people in public places to reduce large-scale gatherings |
PPE: Personal protective equipment; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2.
Unanswered questions about severe acute respiratory syndrome coronavirus 2
|
|
| Where does SARS-CoV-2 really originated from and how does it affect humans? |
| Will the spread of SARS-CoV-2 be a seasonal outbreak? |
| Why is the prevalence of SARS-CoV-2 infection lower in children than in adults? |
| Is the infectivity of a patient positively related to the severity of the disease? |
| What is the proportion of asymptomatic carriers worldwide and what role do they play in transmission? |
| What is the probability that a cured patient is re-infected with SARS-CoV-2? |
| How does SARS-CoV-2 invade other organs than the lung? |
| Can animal experiments find out the specific pathogenesis of SARS-CoV-2 infection? |
| How long will it take to develop effective vaccine or medicine against SARS-CoV-2? |
SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2.